Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-toxicity conditioning regimen based on the use of treosulfan

Blood

Volumn 120, Issue 2, 2012, Pages 473-476

  Bernardo, Maria Ester ^a   Piras, Eugenia ^b   Vacca, Adriana ^b   Giorgiani, Giovanna ^c   Zecca, Marco ^c   Bertaina, Alice ^a   Pagliara, Daria ^a   Contoli, Benedetta ^a   Pinto, Rita Maria ^a   Caocci, Giovanni ^b   Mastronuzzi, Angela ^a   La Nasa, Giorgio ^b   Locatelli, Franco ^a,d  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; THALASSEMIA MAJOR; TREATMENT OUTCOME;

EID: 84864075455     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-423822     Document Type: Article

References (14)

1. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329(12):840-844. (Pubitemid 23267211)
2. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87(5):2082-2088. (Pubitemid 26068926)
3. Locatelli F, De Stefano P. Innovative approaches to hematopoietic stem cell transplantation for patients with thalassemia. Haematologica. 2005;90(12):1592-1594. (Pubitemid 41818989)
4. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 2002;99(12):4350-4356. (Pubitemid 34627200)
5. Locatelli F, Rocha V, Reed W, et al; for the Eurocord Transplant Group CBT. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101(6):2137-2143. (Pubitemid 36302049)
6. Casper J, Knauf W, Kiefer T, et al. Treosulfan and Fludarabine: a new toxicity-reduced conditioning regimen for allogeneic haematopoietic stem cell transplantation. Blood. 2004;103(2):725-731. (Pubitemid 38140111)
7. Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulfan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005;35(3):233-241. (Pubitemid 40268293)
8. Schmidt-Hieber M, Blau IW, Trenschel R, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2007;39(7):389-396. (Pubitemid 46487303)
9. Ruutu T, Volin L, Beelen DW, et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica. 2011;96(9):1344-1350.
10. Wachowiak J, Sykora KW, Cornish J, et al. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 2011;46(12):1510-1518.
11. Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367-4375.
12. Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143(4):548-551.
13. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18(4):295-304.
14. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203. (Pubitemid 39038044)